EASE (Efficacy of ATX01 Study in Erythromelalgia)
Phase 2
Completed
- Conditions
- Erythromelalgia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- AlgoTherapeutix
- Target Recruit Count
- 14
- Registration Number
- NCT05917912
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇩🇪Universitätsklinikum Erlangen Hautklinik, Erlangen, Germany
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
Phase 2
Active, not recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: ATX01 15%Drug: ATX01 10%Drug: Placebo
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AlgoTherapeutix
- Target Recruit Count
- 276
- Registration Number
- NCT05593614
- Locations
- 🇺🇸
HD Research, Bellaire, Texas, United States
🇺🇸Neuroscience Research Center, LLC., Overland Park, Kansas, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
© Copyright 2025. All Rights Reserved by MedPath